On August 19, 2020, the Trump administration made a major announcement that marks the latest development in the ever-evolving saga of the Food and Drug Administration’s (FDA) oversight of laboratory-developed tests (LDTs)....more
10/3/2020
/ CLIA ,
Clinical Laboratories ,
Coronavirus/COVID-19 ,
Department of Health and Human Services (HHS) ,
Diagnostic Tests ,
Food and Drug Administration (FDA) ,
Infectious Diseases ,
Laboratory Developed Tests ,
Legislative Agendas ,
Life Sciences ,
Medical Device User Fee Program (MDUFA IV) ,
Medical Devices ,
Policy Statement ,
Popular ,
Regulatory Oversight ,
Rescission ,
Trump Administration